Colorectal Cancer
Conditions
Keywords
T1 Colorectal Cancer, Early Colorectal Cancer, Endoscopic polypectomy, Oncological Surgery, Lymph node metastasis, Molecular signatures, Disease free survival
Brief summary
The implementation of population screening programs for colorectal cancer (CRC) has led to a considerable increase in the prevalence T1 CRC originating on polyps amenable by endoscopy. The benefits of secondary oncological surgery in terms of disease free survival are not well established. Hypothesis: The characteristics of the individuals and the polyp (endoscopic, histological) should allow us to discriminate T1 CRCs that may benefit from secondary surgery from those that only require local treatment. With the current criteria, the management of patients with T1 CRC is suboptimal since a high proportion of patients are refered for unnecessary surgeries without a clear benefit in terms of survival. Molecular signatures can help to discriminate those patients with good prognosis that do not require secondary surgery nor cancer related follow up.
Detailed description
The primary objective of the study is to compare the effect of oncological surgery versus local treatment for the management of polyps with T1 CRC in relation to disease-free survival and morbi-mortality of the therapeutic procedure. We will also validate molecular signatures in endoscopic samples for the prediction of lymph node metastasis and survival. Methodology: Clinical Study: Retrospective population-based cohort study that will include baseline clinical and follow up data of more than 1400 T1 CRCs in at least 10 Spanish autonomous communities from 2007 to 2017. A centralized pathological review will be carried out by a group of expert pathologists. Inter and intraobserver variability for histological staging will be assessed. A predictive model will be created to discriminate individuals with high probability of receiving surgical and local treatment. For those patients who have a similar probability range, the results in progression-free survival and adverse events will be compared. Translational phase: A 5miRNAs and 8mRNA signature predictive of lymph node metastasis will be assessed in 200 endoscopic samples and related with prognosis.
Interventions
PROCEDURESurgery or Endoscopic treatment
All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
Sponsors
Fundacion Clinic per a la Recerca Biomédica
Hospital Clinic of Barcelona
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
\- All patients diagnosed with pT1 CRC will be included, regardless of endoscopic features, treatment received and lymph node staging
Exclusion criteria
* CRC with other histology than adenocarcinoma * Patients with hereditary syndromes of CRC (Lynch syndrome, classical familial adenomatous polyposis) or inflammatory bowel disease. * Synchronous CRC * Metachronous CRC in the previous 5 years * Patients with metastatic neoplastic disease at the time of diagnosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 1 year | Evaluate the effect of surgery and local (endoscopic) treatment on overall survival (expressed in months) |
| Disease free survival | 1 year | Evaluate the effect of surgery and local (endoscopic) treatment on disease free survival (expressed in months) |
| Develop a predictive model of the probability of receiving surgical treatment | 1 year | Determine factors associated with the choice of primary treatment and final treatment (endoscopic, primary surgery or secondary surgery) and to develop a predictive model that allow discriminate individuals with high probability of receiving surgical treatment |
| Validation of molecular signatures | 2 years | Evaluate the validity of molecular signatures based on mRNA and miRNA (determined in endoscopic samples) for prediction lymph node metastasis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of adverse events | 1 year | Evaluate the proportion of adverse effects after endoscopic or surgical treatment |
| Prognosis | 1 year | Determine the prognosis of patients with pT1CRC in relation to the treatment received (local, primary surgery or secondary surgery) |
| Sensitivity and specificity of follow-up tests | 1 year | To evaluate the performances of the different tests (CT, US, blood markers, colonoscopy) during follow up for detecting recurrence |
| Risk of lymph node metastasis | 1 year | Evaluate the factors of the individual and the polyp that are associated with lymph node metastasis |
| Concordance of histological evaluation | 2 years | Evaluate the inter-intraexplorer concordance of the pathologists for the histological staging criteria. |
| T1 CRC in screening program | 1 year | Compare the characteristics of the T1 CRCs diagnosed within a population screening program and outside it. |
Countries
Spain
Outcome results
None listed